title: Fibroblast growth factor-2 promotes healing of surgically created periodontal defects in rats with early, streptozotocin-induced diabetes via increasing cell proliferation and regulating angiogenesis.
abstract: OBJECTIVE
  To evaluate the effects of fibroblast growth factor (FGF)-2 on the healing of surgical periodontal defects in rats with early, streptozotocin-induced diabetes.
  
  
  METHODS
  Fifty Wistar rats were assigned to streptozotocin-induced diabetes or non-diabetes group. Periodontal defects were surgically created at maxillary first molars. Defects were treated with hydroxypropyl cellulose (HPC) or FGF-2 with HPC. Defect fill was evaluated by microcomputed tomography. Histological and immunohistochemical analyses were performed.
  
  
  RESULTS
  Compared to vehicle alone, FGF-2 treatment yielded significantly greater bone volume and trabecular thickness in diabetes group. Diabetes group displayed reduced new bone formation and significantly longer epithelial down-growth compared to non-diabetes group. In diabetes group, FGF-2 treatment increased PCNA-positive cells and new bone formation after 2 weeks and suppressed epithelial down-growth, but new cementum formation was minimal even after 4 weeks. In diabetes group, overexpression of vascular endothelial growth factor was evident in cells within connective tissue, and no significant enhancement was observed by FGF-2 treatment. FGF-2 increased the expression of α-smooth muscle actin in diabetes group.
  
  
  CONCLUSIONS
  Treatment of surgical periodontal defects in diabetic rats with the single application of FGF-2 provided beneficial effects primarily on new bone formation via increasing cell proliferation and regulating angiogenesis.
authors.affiliation: Department of Periodontology, Tokyo Dental College, Tokyo, Japan.
authors.forename: Takahiro
authors.initials: T
authors.lastname: Bizenjima
authors.forename: Fumi
authors.initials: F
authors.lastname: Seshima
authors.forename: Yoichi
authors.initials: Y
authors.lastname: Ishizuka
authors.forename: Takahiro
authors.initials: T
authors.lastname: Takeuchi
authors.forename: Takashi
authors.initials: T
authors.lastname: Kinumatsu
authors.forename: Atsushi
authors.initials: A
authors.lastname: Saito
mesh_terms: D000199:Actins / Q000032:analysis / Q000187:drug effects; D016301:Alveolar Bone Loss / Q000188:drug therapy*; D000818:Animals; D049109:Cell Proliferation / Q000187:drug effects; D002482:Cellulose / Q000031:analogs & derivatives; D025021:Cementogenesis / Q000187:drug effects; D003238:Connective Tissue / Q000187:drug effects; D003921:Diabetes Mellitus, Experimental / Q000150:complications*; D004337:Drug Carriers; D004846:Epithelial Attachment / Q000187:drug effects; D016222:Fibroblast Growth Factor 2 / Q000494:pharmacology*; D008297:Male; D008439:Maxillary Diseases / Q000188:drug therapy; D008963:Molar / Q000473:pathology; D018919:Neovascularization, Physiologic / Q000187:drug effects*; D010012:Osteogenesis / Q000187:drug effects; D018809:Proliferating Cell Nuclear Antigen / Q000032:analysis; D051381:Rats; D017208:Rats, Wistar; D013311:Streptozocin; D013997:Time Factors; D042461:Vascular Endothelial Growth Factor A / Q000032:analysis / Q000187:drug effects; D014945:Wound Healing / Q000187:drug effects; D055114:X-Ray Microtomography / Q000379:methods
chemical_list: D000199:Actins; D002482:Cellulose; D004337:Drug Carriers; D016222:Fibroblast Growth Factor 2; D018809:Proliferating Cell Nuclear Antigen; D013311:Streptozocin; D042461:Vascular Endothelial Growth Factor A; C498862:Acta2 protein, rat; C467498:vascular endothelial growth factor A, rat; C008079:hydroxypropylcellulose
keywords: FGF-2; VEGF; bone formation; diabetes; periodontal disease; regeneration